Immunogen (IMGN) Cash Flow Statement

Click line-items for a historical chart and %

Net loss	-44.73M
Depreciation and amortization	1.53M
(Gain) loss on sale/disposal of fixed assets	0
Amortization of deferred lease incentive
Gain on sale of marketable securities
Loss (gain) on forward contracts
Stock and deferred share unit compensation	4.5M
Deferred rent	63K
Accounts receivable	567K
Unbilled revenue	-51K
Inventory	-1.12M
Prepaid and other current assets	-2.6M
Restricted cash
Other assets	292K
Accounts payable	-2.12M
Accrued compensation	-3.98M
Other accrued liabilities	38K
Deferred revenue	-74K
Net cash used for operating activities	-47.84M
Proceeds from maturities or sales of marketable securities
Purchases of property and equipment, net	-1.18M
(Payments) proceeds from settlement of forward contracts
Net cash (used for) provided by investing activities	-1.18M
Proceeds from stock options exercised	0
Net cash provided by financing activities	0
Net change in cash and cash equivalents	-49.03M
Cash and cash equivalents, beginning balance	245.03M
Cash and cash equivalents, ending balance	196M

Entities mentioned with IMGN

View All Entities